US 10961305
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 10961305 (Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta) held by Mereo Biopharma 3 Limited expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mereo Biopharma 3 Limited
- Grant date
- Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/663